TALPHERA, INC.
No SEC Form 4 filings for $TLPH in the last 30 days.
See all $TLPH insider activity →Talphera (Nasdaq: TLPH) reported Q2 2026 results and a corporate update on nafamostat. NEPHRO CRRT study enrollment is 75%, expected to finish by year-end. KDIGO 2026 draft guidelines cite nafamostat as an acceptable CRRT anticoagulant. Cash and investments were $17.1M at June 30, 2026; Q2 net loss was $4.3M.
TALPHERA, INC. (TLPH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex_1003190.htm EXHIBIT 99.1 ex_1003190.htm Exhibit 99.1 Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update NEPHRO CRRT clinical study of nafamostat is 75% enrolled; expected to be complete this year Draft 2026 KDIGO guidelines added n
TALPHERA, INC. (TLPH) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 ex_979677.htm EXHIBIT 10.1 ex_979677.htm Exhibit 10.1 AMENDED AND RESTATED 2020 EQUITY INCENTIVE PLAN Originally Adopted by the Board of Directors: April 16, 2020 Originally Approved by the Stockholders: June 16, 2020 Amendment and Restatement Approved by the Board of D
Over the past 7 days, alphai's AI scored 2 news stories mentioning TLPH (TALPHERA, INC.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent TLPH coverage spans financial news, technology and earnings.
Clinical enrollment progress plus a favorable KDIGO guideline reference can improve perceived regulatory/commercial odds for nafamostat, but the company still has no approval datapoint yet.
Near-term catalyst is continued NEPHRO CRRT enrollment toward year-end completion, reinforced by KDIGO guideline language that may improve commercial positioning if approval follows.
This is a corporate governance/compensation disclosure; it may affect near-term sentiment but provides no operational or financial datapoint in the excerpt.
Talphera (TLPH) reported Q3 2025 earnings with mixed results. Revenue exceeded expectations, but profit margins declined due to increased R&D expenses. The company's outlook remains cautiously optimistic amid sector-wide challenges.
Talphera reported a 14% expense reduction alongside a narrower EPS loss, indicating improved operational efficiency. The company's focus on cost management may positively influence future profitability, but the current earnings still reflect losses.
alphai scores every news story that mentions TLPH with an AI model for sentiment and relevance, and aggregates insider trades from TALPHERA, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Talphera (Nasdaq: TLPH) reported Q2 2026 results and a corporate update on nafamostat. NEPHRO CRRT study enrollment is 75%, expected to finish by year-end. KDIGO 2026 draft guidelines cite nafamostat as an acceptable CRRT anticoagulant. Cash and investments were $17.1M at June 30, 2026; Q2 net loss was $4.3M.
4 min readTALPHERA, INC. (TLPH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex_1003190.htm EXHIBIT 99.1 ex_1003190.htm Exhibit 99.1 Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update NEPHRO CRRT clinical study of nafamostat is 75% enrolled; expected to be complete this year Draft 2026 KDIGO guidelines added n
6 min readTALPHERA, INC. (TLPH) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 ex_979677.htm EXHIBIT 10.1 ex_979677.htm Exhibit 10.1 AMENDED AND RESTATED 2020 EQUITY INCENTIVE PLAN Originally Adopted by the Board of Directors: April 16, 2020 Originally Approved by the Stockholders: June 16, 2020 Amendment and Restatement Approved by the Board of D
3 min readImage source: The Motley Fool.Wednesday, November 12, 2025 at 4:30 p.m. ETNeed a quote from a Motley Fool analyst? Email pr@fool.comContinue reading ...
5 min readTalphera ( NASDAQ:TLPH ) , a specialty pharmaceutical company developing therapies for medically supervised hospital settings, reported its second quarter 2025 results on August 14, 2025. The company posted an EPS loss of $0.10 ( GAAP ) , which was better than the analyst consensus estimate of a ...
2 min readTalphera ( NASDAQ:TLPH ) reported second quarter 2025 results on August 14, 2025, highlighting accelerated clinical trial enrollment and a reduction in annual cash operating expense guidance to $16 million-$17 million for 2025.
2 min readImage source: The Motley Fool.Thursday, Aug. 14, 2025 at 4:30 p.m. ETChief Executive Officer - Vincent AngottiContinue reading ...
3 min readTalphera (TLPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
2 min read
